Filing summary
Entity note: The request identifies GYRE THERAPEUTICS, INC., but the supplied Form 10-Q is for Catalyst Biosciences, Inc. This summary reflects the filing text provided, for the quarter ended June 30, 2017.
Business context and reporting period
Catalyst was a clinical-stage biotechnology company developing protease-based medicines, with a focus on hemophilia. Its lead programs were marzeptacog alfa (activated), a Factor VIIa variant, and CB 2679d/ISU304, a Factor IX variant. The unaudited filing reports results for the three and six months ended June 30, 2017, compared with the same periods in 2016.
Financial performance and liquidity
- Revenue: Contract revenue was $111,000 in Q2 2017, versus $109,000 in Q2 2016. First-half revenue was $382,000, up from $219,000. All contract revenue came from the ISU Abxis collaboration; there were no commercial product sales.
- Expenses and losses: Q2 operating expenses rose 21% to $6.1 million; research and development (R&D) was $3.4 million and general and administrative (G&A) was $2.7 million. Q2 net loss was $5.9 million, compared with $4.8 million. First-half operating expenses rose 8% to $10.5 million, and net loss increased to $10.0 million from $8.4 million.
- Common-stockholder loss: First-half net loss attributable to common stockholders was $14.0 million, including a $4.0 million non-cash deemed dividend for the preferred-stock beneficial conversion feature. Basic and diluted loss per share was $5.82 for the first half, versus $11.05 in 2016; per-share comparisons are affected by the 2017 reverse split and increased share count.
- Cash flow: First-half cash used in operations was $8.7 million, versus $8.4 million. Investing activities provided $6.8 million, primarily from investment maturities. Financing activities provided $24.1 million, principally from the April offering and at-the-market stock sales; note redemptions were offset by releases of restricted cash.
- Liquidity and obligations: Cash and cash equivalents were $32.4 million at June 30, 2017, with no short-term investments. A further $6.0 million was restricted, including $5.8 million securing redeemable convertible notes. The notes had a $5.8 million balance, due at maturity in February 2018 if not previously redeemed or converted. Total liabilities were $9.3 million and stockholders’ equity was $30.3 million. Management said available capital was expected to fund operations for at least 12 months from the filing date.
- Margins: The filing does not provide a meaningful product gross margin; revenue was collaboration-based and the company had no commercial product sales.
Material changes versus prior comparable periods
- Q2 R&D expense increased 24%, driven mainly by $1.3 million of additional marzeptacog alfa manufacturing expense, partly offset by lower personnel costs after a 2016 workforce reduction. First-half R&D rose 9% as manufacturing costs increased, partly offset by lower personnel, laboratory and preclinical costs.
- First-half G&A rose 8%, reflecting personnel and professional-service costs, including costs associated with the April 2017 offering.
- First-half interest and other income fell to $101,000 from $1.1 million, primarily because 2016 included a $1.0 million gain from a change in the fair value of a derivative liability.
- In April 2017, the company raised approximately $18.6 million net through an offering of common stock, Series A preferred stock and warrants. It also received $5.3 million net from at-the-market common-stock sales during the first half; no shares remained available under that program at June 30.
- The company completed a 1-for-15 reverse stock split in February 2017. Common shares outstanding were 4,310,561 at June 30, versus 801,756 at December 31, 2016.
Outlook, commentary and risks
- Management expected to advance marzeptacog alfa into the Phase 2 portion of a Phase 2/3 subcutaneous prophylaxis trial in 2017. ISU Abxis began a Phase 1/2 trial of CB 2679d/ISU304 in June 2017; Catalyst expected enrollment of up to 17 subjects, completion in Q1 2018 and top-line data by year-end 2017.
- Management anticipated higher R&D spending in coming quarters, particularly for clinical development and manufacturing. The company had delayed further Factor Xa work and was exploring licensing opportunities for its anti-complement programs to focus resources on the hemophilia pipeline.
- The company had never been profitable and expected significant expenses and operating losses for at least several years. Management cautioned that its 12-month funding estimate depended on assumptions and that additional financing might be needed; unavailable or unfavorable financing could force program delays, reductions or discontinuation.
- Key development risks include clinical-trial outcomes, regulatory approval, manufacturing execution, competition and commercial viability. Catalyst depended on ISU Abxis for the CB 2679d/ISU304 Phase 1/2 development, and the collaboration could be delayed or terminated.
- Contractual obligations included $499,000 of operating lease payments and approximately $1.3 million remaining under the CMC manufacturing agreement. Potential milestone payments of up to $17.5 million to Pfizer and up to $2.0 million to ISU Abxis were excluded from contractual obligations because timing and achievement were uncertain. No material legal proceedings or off-balance-sheet arrangements were reported.
- Controls and procedures were assessed as effective at the reasonable-assurance level; no material change in internal control over financial reporting was reported for the first half.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing is Catalyst Biosciences, not Gyre Therapeutics.
- Check the terms, conversion and redemption status of the remaining $5.8 million notes and the availability of restricted cash securing them.
- Track cash burn against the stated 12-month runway, planned clinical/manufacturing spending and the need for additional financing.
- Verify progress, timing and results for the marzeptacog alfa and CB 2679d/ISU304 trials, including the expected 2017 top-line data for the latter.
- Assess dilution and potential share overhang from preferred-stock conversion rights and the 2.05 million outstanding warrants exercisable at $5.50 per share.